Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Larotrectinib Capsules, 25 mg and 100 mg. The Company has enclosed its press release.
The above information is a part of company’s filings submitted to BSE.